San Diego-based Tragara Pharmaceuticals, a developer of biopharmaceuticals aimed at cancer and inflammation treatments, has raised another $5M in a funding round, according to a regulatory filing by the firm last week. The filing indicates the equity funding comes as part of an ongoing, $10M fundraising effort by the company. No details on the funding have been announced by the firm. The firm has previously raised funding from Domain Associates, Proquest Investments, Mitsubishi, Morgenthaler Ventures, and Oxford Bioscience Partners. The firm last raised a large, $40M funding round in 2007. More information »